Bioceres Crop Solutions (BIOX) Expected to Announce Quarterly Earnings on Monday

Bioceres Crop Solutions (NASDAQ:BIOX) will likely be announcing its Q1 2026 results before the market opens on Monday, November 10th. Analysts expect the company to announce earnings of ($0.04) per share and revenue of $90.2250 million for the quarter. Investors may visit the the company’s upcoming Q1 2026 earningresults page for the latest details on the call scheduled for Thursday, November 13, 2025 at 8:30 AM ET.

Bioceres Crop Solutions Stock Up 18.0%

Shares of NASDAQ:BIOX opened at $2.03 on Monday. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 0.22. The business has a fifty day moving average of $1.95 and a two-hundred day moving average of $3.40. The stock has a market cap of $127.30 million, a P/E ratio of -2.51 and a beta of 0.33. Bioceres Crop Solutions has a 52-week low of $1.20 and a 52-week high of $7.44.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Bank of America Corp DE boosted its holdings in Bioceres Crop Solutions by 186.8% during the 4th quarter. Bank of America Corp DE now owns 5,735 shares of the company’s stock valued at $35,000 after acquiring an additional 3,735 shares during the period. Jones Financial Companies Lllp boosted its holdings in Bioceres Crop Solutions by 3,535.8% during the 1st quarter. Jones Financial Companies Lllp now owns 5,490 shares of the company’s stock valued at $25,000 after acquiring an additional 5,339 shares during the period. Jane Street Group LLC purchased a new position in Bioceres Crop Solutions during the 2nd quarter valued at about $202,000. Finally, PDT Partners LLC boosted its holdings in Bioceres Crop Solutions by 58.9% during the 2nd quarter. PDT Partners LLC now owns 28,180 shares of the company’s stock valued at $126,000 after acquiring an additional 10,449 shares during the period. Hedge funds and other institutional investors own 17.68% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on BIOX shares. Weiss Ratings restated a “sell (d)” rating on shares of Bioceres Crop Solutions in a report on Wednesday, October 8th. Wall Street Zen cut Bioceres Crop Solutions from a “hold” rating to a “sell” rating in a report on Saturday, September 13th. Oppenheimer cut Bioceres Crop Solutions from an “outperform” rating to a “market perform” rating in a report on Wednesday, October 22nd. Lake Street Capital dropped their target price on Bioceres Crop Solutions from $8.00 to $5.00 and set a “buy” rating for the company in a report on Wednesday, September 10th. Finally, Canaccord Genuity Group restated a “hold” rating and issued a $2.50 target price (down from $6.50) on shares of Bioceres Crop Solutions in a report on Wednesday, September 10th. One equities research analyst has rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Bioceres Crop Solutions has a consensus rating of “Hold” and an average price target of $4.17.

Bioceres Crop Solutions Company Profile

Bioceres Crop Solutions Corp., together with its subsidiaries, provides crop productivity solutions. It operates through Seed and Integrated Products, Crop Protection, and Crop Nutrition segments. The Seed and Integrated Products segment provides seed traits, germplasms, and seed treatment packs for healthier, and higher yielding crops.